2026 International Forum on Life Sciences Innovation, R&D Collaboration and Investment: Connecting HKEX, Multinationals, Listed Companies & Pioneering Innovators
Foreword
In 2025, the Hong Kong stock market made a strong comeback, with$37.4 billionFundraising Amount Reclaims Top Spot in Global IPOs! Stronger Momentum at the Start of 2026, with Equity Financing Scale in January Surging Sixfold Year-on-Year to$15.8 billion, the capital feast of the Year of the Horse has already begun.
This forum will bring togetherHKEX executives, drug regulatory authorities, heads of multinational healthcare collaborations, listed companies, and top-tier investment institutionsand more, to precisely identify the golden window for Hong Kong-listed stocks in 2026, connect with global capital, and jointly expand new frontiers of internationalization.
Main Forum Registration Channel
Limited-Time Free Registration
Forum Planning Highlights
Highlight 1
【Prospective HKEX-listed Companies】in Dialogue with【HKEX】
Zhang Xiaoxia
Vice President, Global Listing Services Division, Hong Kong Exchanges and Clearing Limited
What Are the New Listing Rules for HKEX in 2026?
What Is the Fastest Path to an IPO in Hong Kong?
How Many Steps Away Is Your Company from Listing on the Hong Kong Stock Exchange?
【[HKEX Matchmaking Event] Invitation Channel
[For Medical Enterprises Only]
Limited spots available—register now.
Remarks:Please register your company and complete the [Topics for Discussion with HKEX] in advance, so that we can better facilitate your engagement with the Hong Kong Stock Exchange.
Highlight 2
Global Pharmaceutical and Medical Device Industry Association
Empowering the Formulation of Global Industry Standards and Leading Innovation
Liu Xiang
Vice President, Global, and Executive Director, China, Advanced Medical Technology Association (AdvaMed)
Tan Junhui
Pharmaceutical Research and Manufacturers of America (PhRMA)
Chief Representative, China Region
Highlight 3
Guests from Academic and Industry Partner Organizations
Multinational Corporation ✖️ Publicly Listed Company ✖️ Benchmark Innovative Enterprise
Highlight 4
Selected Lead Investors
Key Investment Areas: Biopharmaceuticals, High-End Medical Devices
Agenda
(Draft Agenda and Guests)
9:00 AM–12:00 PM HKEX Matchmaking Session
9:00-12:00HKEX and Liaison Meeting with Enterprises Listing in Hong Kong
In-Depth Engagement Between the Hong Kong Stock Exchange and Innovative Medical Companies Planning to Go Public
PM 13:00-18:00 Main Forum
13:00-13:30Guest Check-in
13:30-13:45 Leader's Address
13:45-14:05
Investment and Policy Promotion for the Life and Health Industry in Nanjing Jiangning Development Zone
14:05-14:25Keynote Address by Leaders of the Jiangsu Provincial Medical Products Administration
Relevant Policies on Priority Review and Approval for Drugs and Medical Devices in Jiangsu Province
14:25-14:45Academician Keynote Speech
Ma DaweiAcademician of the Chinese Academy of Sciences, Researcher at the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
14:45-14:55Tea Break
14:55-15:15 Keynote Sharing
2026 Healthcare Innovation Companies Listing in Hong Kong: Interpretation of HKEX’s New Regulations and Future Trends
Zhang Xiaoxia, Vice President, Global Listing Services, Hong Kong Exchanges and Clearing Limited
15:15-15:55 [Pharmaceutical Roundtable Discussion]
Strategic New Directions and Collaboration for Multinational and Chinese Pharmaceutical Companies
Zhang LianshanDirector, Executive Vice President, and President of Global R&D at Hengrui Medicine
Xie XinExecutive Director and Senior Vice President of Sino Biopharmaceutical
Chen XiaojingSenior Vice President, Eli Lilly China
Yan ShuiLoyaltyChief Operating Officer, Global R&D, Zai Lab
Niu YingHead of China Search and Evaluation, Pfizer Global Business Development
Li XiangFounder and Chairman of Shize Biotech
Li ZonghaiChairman of CARsgen Therapeutics
Travis TannerChief Representative, China, of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15:55-16:35 【Medical Device Roundtable Discussion】
Systemic Innovation in Technology, Clinical Practice, and Industry within the Innovative Medical Device Sector
Gu YushaoSenior Vice President, Medtronic plc, and President, Greater China
Cai HongbinDirector and Executive Deputy General Manager of Sanbo Brain Hospital Group
Peng LeiFounder and General Manager of Gestalt Technology
Cao HongguangFounder and Chairman of Suzhou Newlink Medical Technology Co., Ltd.
Wang DaoyuFounder of Zhuodao Medical
Bian RuiVice President, Boston Scientific China
Tang NingVice President, Sonova China
Liu XiangVice President, Global and Executive Director, China, AdvaMed
16:35-17:15 [Capital and Corporate Cooperation Roundtable]
New Models of Capital Flow for Biomedical Enterprises
Xiao ZhiDeputy General Manager, SDIC Innovation Investment Management Co., Ltd.
Jiang LiManaging Director, China Life Equity Investment
Wu WeiHead of JJDC Asia Pacific, Johnson & Johnson Innovation
Ma YanManaging Director, FountainVest Partners
17:15-18:00
Jiangning Development Zone, Enterprises, and Investment Institutions Engage in Free Networking and Collaborative Exchange
Evening: Jiangning Banquet
18:30-20:30
Corporate & Investment Institutions · Jiangning Dinner
Partner Media
Main Forum Registration
Limited-Time Free Registration
【[HKEX Matchmaking Session] Invitation Channel
[Medical Enterprises Only]
Limited spots available; register early.
Remarks:Participating companies are requested to complete in advance the section on [Topics for Discussion with the HKEX] to facilitate our support in coordinating your engagement with the Hong Kong Exchanges and Clearing Limited.